Africa carries 25% of the global hepatitis B burden, yet the cascade of care — s...
Africa Trials
50
US Trials
3,477
Gap Ratio
70x
Nations
54
Key Finding
Africa hosted 50 hepatitis B trials versus 3,477 in the United States, a 70-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Africa carries 25% of the global hepatitis B burden, yet the cascade of care — screening, diagnosis, treatment — has trial gaps at every stage, especially in cure-focused research.
The Evidence 138 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of hepatitis B trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 50 hepatitis B trials (0.2% of its portfolio) compared to 3,477 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of hepatitis B trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 50 hepatitis B trials (0.
Interpretation
2% of its portfolio) compared to 3,477 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by reliance on ClinicalTrials.
Extra
gov alone, which may undercount locally registered African studies.